Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Analysis of CRx-191 in Psoriasis - Comments

November 12, 2007

Analysis of:CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis | www.pipelinereview.com

The combination of a topical steroid with an antidepressant seems to be intriguing. Antidepressant have shown some anti-pruritic activity in atopic dermatitis. The major disadvantage of the current investigational drug is the sue with occlussive dressings. That makes it impossible to use the drug for larger body areas covered by psoriasis. The same is true for facial lesions. Nevertheless, the idea behind this drug is challenging.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS